Inventor · disambiguated record
Pierre Van Der Bruggen
Also filed as: BRUGGEN PIERRE VAN DER · VAN DER BRUGGEN PIERRE · VAN DER BRUGGEN PIERRE B
74 granted patents·4 pending applications·1,352 citations·filing 1991–2015
99Inventor score
Files withLUDWIG INST CANCER RES71BOON-FALLEUR THIERRY1DEMOTTE NATHALIE1EBERTS DANIELA1Johannes Gutenberg-Universität Mainz1
Top patents by PatentIndex Score
78 records- 0196US5342774ANucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1LUDWIG INST CANCER RES·Filed 1991·Granted Aug 30, 1994·232 cites·18 claims
- 0294US7311914B2MAGE-A4 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Dec 25, 2007·67 cites·11 claims
- 0394US5405940AIsolated nonapeptides derived from MAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 1992·Granted Apr 11, 1995·129 cites·9 claims
- 0491US5571711AIsolated nucleic acid molecules coding for BAGE tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1993·Granted Nov 5, 1996·69 cites·11 claims
- 0588US8349558B2Detection of individual T-cell reaction patterns against tumor-associated antigens (TAA) in tumor patients as a basis for the individual therapeutic vaccination of patientsUNIV MAINZ JOHANNES GUTENBERG·Filed 2007·Granted Jan 8, 2013·24 cites·13 claims
- 0688US7049413B2MAGE-A3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2001·Granted May 23, 2006·11 cites·19 claims
- 0786US8951747B2Method for modulating activity of T lymphocytesDEMOTTE NATHALIE·Filed 2012·Granted Feb 10, 2015·7 cites·14 claims
- 0886US6291430B1Mage-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 1998·Granted Sep 18, 2001·48 cites·15 claims
- 0985US5965535AMage-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 1997·Granted Oct 12, 1999·51 cites·11 claims
- 1085US5683886ATumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Nov 4, 1997·51 cites·6 claims
- 1183US6426217B1MAGE-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2000·Granted Jul 30, 2002·17 cites·16 claims
- 1280US6235525B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereofLUDWIG INST CANCER RES·Filed 1993·Granted May 22, 2001·27 cites·10 claims
- 1379US5585461AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Dec 17, 1996·39 cites·4 claims
- 1478US6034214AIsolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cellsLUDWIG INST CANCER RES·Filed 1994·Granted Mar 7, 2000·40 cites·4 claims
- 1578US5462871AIsolated nucleic acid molecules which encode MAGE derived nonapeptidesLUDWIG INST CANCER RES·Filed 1993·Granted Oct 31, 1995·52 cites·16 claims
- 1677US5554506AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Sep 10, 1996·31 cites·3 claims
- 1776US7388072B2MAGE peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2003·Granted Jun 17, 2008·5 cites·21 claims
- 1876US5591430AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jan 7, 1997·35 cites·6 claims
- 1975US6939707B2Isolated nucleic acid molecules which encode GAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 2001·Granted Sep 6, 2005·3 cites·9 claims
- 2075US6531451B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1999·Granted Mar 11, 2003·24 cites·2 claims
- 2175US5925729ATumor rejection antigen precursors, tumor rejection antigens and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jul 20, 1999·31 cites·1 claims
- 2274US7199231B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Apr 3, 2007·3 cites·12 claims
- 2374US6946289B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Sep 20, 2005·1 cites·6 claims
- 2473US5965381ADelivery of proteins into eukaryotic cells with recombinant yersiniaLUDWIG INST CANCER RES·Filed 1998·Granted Oct 12, 1999·28 cites·64 claims
- 2573US5554724AIsolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereofUNIV LEIDEN·Filed 1994·Granted Sep 10, 1996·36 cites·4 claims
- 2672US5695994AIsolated cytolytic T cells specific for complexes of MAGE related peptides and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 9, 1997·20 cites·6 claims
- 2770US6682731B1Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 moleculesLUDWIG INST CANCER RES·Filed 2000·Granted Jan 27, 2004·3 cites·2 claims
- 2869US6488932B1Method for treating cancer by administering MAGE-derived peptidesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 3, 2002·25 cites·4 claims
- 2968US7488793B2Isolated peptide which binds to HLA-Cw*07 and uses thereofLUDWIG INST CANCER RES·Filed 2004·Granted Feb 10, 2009·4 cites·4 claims
- 3067US7041502B2Isolated peptides which bind to HLA-B18 molecules and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted May 9, 2006·2 cites·11 claims
- 3167US5851523AIsolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Dec 22, 1998·20 cites·7 claims
- 3266US7351409B2Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 2004·Granted Apr 1, 2008·3 cites·2 claims
- 3366US2009203124A1Mage-a3 peptides presented by hla-dr1 moleculesLUDWIG INST CANCER RES·Filed 2008·Application pending·0 cites
- 3465US5858689AIsolated peptides derived from the gage tumor rejection antigen precursor and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Jan 12, 1999·15 cites·4 claims
- 3563US5686068AIsolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Nov 11, 1997·30 cites·7 claims
- 3663US5558995APeptides which are derived from tumor rejection antigen precursor molecule MAGE-1, which complex to MHC molecule HLA-C clone 10, and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Sep 24, 1996·17 cites·7 claims
- 3762US6369211B1MAGE-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 1999·Granted Apr 9, 2002·10 cites·17 claims
- 3860US7252825B2MAGE-3 peptides presented by HLA class II moleculesUNIV BRUXELLES·Filed 2002·Granted Aug 7, 2007·0 cites·13 claims
- 3960US6063900AIsolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted May 16, 2000·9 cites·9 claims
- 4057US6222012B1Isolated nonapeptides presented by HLA molecules, and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Apr 24, 2001·10 cites·7 claims
- 4157US5763155AMethod for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3 gene productsLUDWIG INST CANCER RES·Filed 1996·Granted Jun 9, 1998·16 cites·2 claims
- 4257US5629166AMethod for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-C-clone 10/MAGE-1 derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1994·Granted May 13, 1997·13 cites·7 claims
- 4355US6353089B1Method for stimulating CTLs with peptidesLUDWIG INST CANCER RES·Filed 1999·Granted Mar 5, 2002·6 cites·4 claims
- 4452US6429287B1Isolated molecules which complex with HLA-Cw*16 molecules, and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Aug 6, 2002·0 cites·4 claims
- 4552US6379901B1Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Apr 30, 2002·12 cites·2 claims
- 4652US6019987AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1996·Granted Feb 1, 2000·7 cites·8 claims
- 4751US6602506B1Delivery of proteins into eukaryotic cells with recombinant YersiniaLUDWIG INST CANCER RES·Filed 1999·Granted Aug 5, 2003·6 cites·28 claims
- 4851US2005249743A1Isolated peptides which bind to HLA-A24 molecules and uses thereofBOON-FALLEUR THIERRY·Filed 2005·Application pending·0 cites
- 4950US5763165AMethod for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3LUDWIG INST CANCER RES·Filed 1994·Granted Jun 9, 1998·14 cites·11 claims
- 5048US6710172B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1999·Granted Mar 23, 2004·7 cites·1 claims
Showing the top 50 of 78 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Pierre Van Der Bruggen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →